Intestinal bacteria and ulcerative colitis

Current Issues in Intestinal Microbiology

Volumn 4, Issue 1, 2003, Pages 9-20

  Cummings, J H ^a   Macfarlane, G T ^a   Macfarlane, S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; IMMUNOGLOBULIN G; METRONIDAZOLE; NEOMYCIN; PENICILLIN G; PROBIOTIC AGENT; RIFAMYCIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANIMAL MODEL; BACTERIAL COUNT; BIFIDOBACTERIUM; CLINICAL TRIAL; COLON MUCOSA; COMMENSALISM; DIARRHEA; DRUG ABSORPTION; DRUG METABOLISM; DRUG TARGETING; ENTERITIS; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNE SYSTEM; INTESTINE FLORA; LACTOBACILLUS; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SPECIES DIFFERENCE; ULCERATIVE COLITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTEROIDES; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; HUMANS; INTESTINAL MUCOSA; PROBIOTICS; SULFATES;

ANIMALIA; BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; ENTEROCOCCUS; LACTOBACILLUS; POSIBACTERIA;

EID: 0037358408     PISSN: 1466531X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Anwar, H., Dasgupta, M.K., and Costerton, J.W. 1990. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob. Ag. Chemother. 34: 2043-2046.
2. Aslam, M., Batten, J.J., Florin, T.H.J., Sidebotham, R.L., and Baron, J.H. 1992. Hydrogen sulphide induced damage to the mucosal barrier in the rat. Gut. 33: S69.
3. Bamba, T., Matsuda, H., Endo, M., and Y. Fujiyama, Y. 1995. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J. Gastroenterol. 30 (Suppl. 8): 45-47.
4. Belsheim, M., Darwisk, R., and M. Watson, M. 1983. Bacterial L-form isolation from inflammatory bowel disease patients. Gastroenterology. 85: 364-369.
5. Brigidi, P., Swennen, E., Rizzello, F., Bozzolasco, M. and Matteuzzi, D. 2002. Effects of rifaximin administration on the intestinal microbiotia in patients with ulcerative colitis. J. Chemotherapy. 14: 290-295.
6. Burke, D., and Axon, A. 1988. Adhesive E. coli in inflammatory bowel disease and infective diarrhoea. BMJ. 297: 102-104.
7. Burke, D.A., Axon, A.T.R., Clayden, S.A., Dixon, M.F., Johnston, D. and Lacey, R.W. 1990. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment. Pharmacol. Therapeut. 4: 123-129.
8. Campieri, M. and Gionchetti, P. 2001. Bacteria as the cause of ulcerative colitis. Gut. 48: 132-135.
9. Campieri, M., and Gionchetti, P. 1999. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? Gastroenterology. 116: 1246-1260.
10. Casellas, F., Borruel, N., Papo, M., Guarner, F., Antolin, M., Videla, S. and Malagelada, J.R. 1998. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm. Bowel Dis. 4: 1-5.
11. Chadwick, V.S. 1991. Etiology of chronic ulcerative colitis and Crohn's disease. In: The Large Intestine: Physiology, Pathophysiology and Disease. S.F. Phillips, J.H. Pemberton, and R.G. Shorter RG, ed. Raven Press Ltd., New York. p. 445-463.
12. Chapman, R.W., Selby, W.S. and Jewell, D.P. 1986. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 27: 1210-1212.
13. Christl, S., Eisner, H.D., Kasper, H., and Scheppach, W. 1996. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig. Dis. Sci. 41: 2477-2481.
14. Cohavy, O., Bruckner, D., Gordon, L.K., Misra, R., Wei, B., Eggena, M.E., Targan, S.R., and Braun, J. 2000. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect. Immun. 68: 1542-1548.
15. Cohen, M.B., and Giannella, R.A. 1991. Bacterial infections: pathophysiology, clinical features and treatment. In: The Large Intestine: Physiology, Pathophysiology and Disease. S.F. Phillips, J.H. Pemberton, and R.G. Shorter, ed. Raven Press Ltd., New York. p. 395-428.
16. Croucher, S.C., Houston, A.P., Bayliss, C.E., and Turner, R.J. 1983. Bacterial populations associated with different regions of the human colon wall. Appl. Environ. Microbiol. 45: 1025-1033.
17. Cummings, J.H., Banwell, J.G., Segal, I., Coleman, N., Englyst, H.N., and Macfarlane, G.T. 1990. The amount and composition of large bowel contents in man. Gastroenterology. 98: A408.
18. Cummings, J.H., Bingham, S.A.,. Heaton, K.W. and Eastwood, M.A. 1992. Fecal weight, colon cancer risk and dietary intake of non-starch polysaccharides (dietary fiber). Gastroenterology 103: 1783-1789.
19. Cummings, J.H. and Macfarlane, G.T. 1999. Are bacterial sulphur metabolites toxins in ulcerative colitis? In: Helicobacter meets inflammatory bowel disease. T. Shimoyama, A. Lee, A. Axon, D. K. Podolsky and C. O'Morain. ed. Axel Springer Japan Publishing Inc. p. 79-99.
20. Cummings, J.H. and Macfarlane, G.T. 2001. Is there a role for microorganisms? In: Challenges in inflammatory bowel disease. D.P. Jewell, B.F. Warren and N.J. Mortensen ed. Blackwell Science Ltd., Oxford. pp. 42-51.
21. Danzi, J.T. 1989. Trimethoprim-sulfamethoxazole therapy of inflammatory bowel disease. Gastroenterology. 96: A110.
22. Dickinson, R.J., O'Connor, H.J., Pinder, I., Hamilton, I., Johnston, D. and Axon, A.T.R. 1985. Double blind controlled trial of oral vancomycin in adjunctive treatment in acute exacerbation of idiopathic colitis. Gut. 26: 1380-1384.
23. DuPont, H.L., Ericsson, C.D., Mathewson, J.J., Palazzini, E., DuPont, M.W., Jiang, Z.D., Mosavi, A. and de la Cabada, F.J. 1998. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion. 59: 708-714.
24. Elson, C.O., Sartor, R.B., Tennyson, G.S. and Riddell, RH. 1995. Experimental models of inflammatory bowel disease. Gastroenterology. 109: 1344-1367.
25. Eve. I.S. 1966. A review of the physiology of the gastrointestinal tract in relation to radiation doses from radioactive materials. Health Phys. 12: 131-161.
26. Fabia, R, Ar'Rajab, A., Johansson, M.-L., Andersson, R., Willen, R., Jeppsson, B., Molin, G., and Bengmark, S. 1993b. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 54: 248-255.
27. Fabia, R., Ar'Rajab, A., Johansson, M.-L., Willen, R., Molin, G., and Bengmark, S. 1993a. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand. J. Gastroenterol. 28: 155-162.
28. Farrell, R.J. and LaMont, J.T. 2002. Microbial factors in inflammatory bowel disease. Gastroenterol. Clin. North Am. 31: 41-62.
29. Farrell, R.J. and Peppercorn, M.A. 2002. Ulcerative colitis. Lancet. 359: 331-340.
30. Fiocchi, C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 115: 182-205.
31. Fox, J.G., Dewhirst, F.E., Fraser, G.J., Paster, B.J., Shames, B. and Murphy, J.C. 1994. Intracellular Campylobacter-like organism from ferrets and hamsters with proliferative bowel disease is a Desulfovibrio sp. J. Clin. Microbiol. 32: 1229-1237.
32. Gardiner, K.R., Halliday, M.I., Barclay, G.R., Milne, L., Brown, D., and Stephens, S. 1995. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 36: 897-901.
33. Gebhart, C.J., Barns, S.M., McOrist, S., Lin , G.-F., and Lawson, G.H.K. 1993. Ileal Symbiont Intracellularis, an obligate intracellular bacterium of porcine intestines showing a relationship to Desulfovibrio species. Int. J. Sys. Bacteriol. 43: 533-538.
34. Gibson, G.R., Cummings, J.H., and Macfarlane, G.T. 1991. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 86: 103-112.
35. Gibson, G.R., Macfarlane, S., and Macfarlane, G.T. 1993. Metabolic interactions involving sulphate-reducing and methanogenic bacteria in the human large intestine. FEMS Microbiol. Ecol. 12: 117-125.
36. Gilat, T., Leichtman, G., Delpre, G., Eschar, J., Bar-Meir, S. and Fireman, Z. 1989. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J. Clin. Gastroenterol. 11: 392-395.
37. Gilat, T., Suissa, A., Leichtman, G., Delpre, G., Pavlotzky, M., Grossman, A. and Fireman, Z. 1987. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J. Clin. Gastroenterol. 9: 415-417.
38. Gionchetti, P., Ferrieri, A., Venturi, A., Brignola, C., Peruzzo, S., Raule, E., Descombe, J.J., Picard, M. and Campieri, M. 1997. Rifaximin, a non-absorbable antibiotic in treatment of steroid-resistant ulcerative colitis: A double-blind placebo controlled trial. Gastroenterology. 112: A1072.
39. Gionchetti, P., Rizzello, F., Venturi, A., Ugolini, F., Rossi, M., Brigidi, P., Johansson, R., Ferrieri, A., Poggiologi, G. and Campieri, M. 1999. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment. Pharmacol. Ther. 13: 713-718.
40. Hans, A.U., Scholmerich, J., Gross, V. and Falk, W. 2000. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur. J. Gastroenterol. Hepatol. 12: 267-273.
41. Hartley, M.G., Hudson, M.J., Swarbrick, E.T, Gent, A.E., Hellier, M.D. and Grace, R.H. 1993. Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis. Gut. 34: 63-67.
42. Hartley, C.L., Neumann, C.S., and Richmond, M.H. 1979. Adhesion of commensal bacteria to the large intestine wall in humans. Infect. Immun. 23: 128-132.
43. Hooper, L.V., Wong, M.H., Thelin, A., Hansson, L., Falk, P.G. and Gordon, J.I. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 291: 881-884.
44. Jiang, Z.D., Ke, S., Palazzini, E., Riopel, L. and Dupont, H. 2000. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Ag. Chemother. 44: 2205-2206.
45. Kennedy, R.J., Hoper, M., Weir, H., Deodhar, K., Erwin, P., Sloan, J., Kirk, S.J. and Gardiner, K.R. 2000. Probiotic therapy stabilises the gut mucosal barrier in the IL-10 knockout model of mouse colitis. Br. J. Surg. 87: 669-670.
46. Kruis, W., Schutz, E., Fric, P., Fixa, B., Judmaier, G. and Stolte, M. 1999. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11: 853-858.
47. Linskens, R.K., Huijsdens, X.W., Savelkoul, P.H.M., Vandenbroucke-Grauls, C.M.J.E. and Meuwissen, S.G.M. 2001. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand. J. Gastroenterol. 36: 29-40.
48. Lobo, A.J., Burke, D.A., Sobala, G.M. and Axon, A.T.R. 1993. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment. Pharmacol. Ther. 7: 155-158.
49. Loftus, E.V., Silverstein, M.D., Sandborn, W.J., Tremaine, W.J., Harmsen, W.S. and Zinsmeister, A.R. 2000. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 46:336-343.
50. Loubinoux, J., Bronowicji, J.-P., Pereira, I.A.C., Moungenel, J.-L., and Faou, A.E. 2002. Sulfate-reducing bacteria in human feces and their association with inflammatory diseases. FEMS Microbiol. Ecol. 40: 107-112.
51. Lukas, M., Konecny, M. and Zboril. V. 2002. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology. 122: A434.
52. Macfarlane, G.T., and Gibson, G.R. 1995. Bacterial infections and diarrhea. In: Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. G.R. Gibson, and G.T. Macfarlane, ed. CRC Press, Boca Raton. p. 201-226.
53. Macfarlane, S., Cummings, J.H., and Macfarlane, G.T. 1999. Bacterial colonisation of surfaces in the large intestine. In: Colonic Microflora, Nutrition and Health. G.R. Gibson, and M. Roberfroid, ed. Chapman and Hall, London, p. 71-87.
54. Macfarlane, S., Hopkins, M.J., and Macfarlane, G.T. 2000. Bacterial growth and metabolism on surfaces in the large intestine. Microb. Ecol. Hlth. Dis. 2: 64-72.
55. Macpherson, A., Khoo, U.Y., Forgacs, I., Philpott-Howard, J., and Bjarnason, I. 1996. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 38: 365-375.
56. Madsen, K.L., Doyle, J.S., Jewell, L.D., Tavernini, M.M., and Fedorak, R.N. 1999. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 116: 1107-1114.
57. Madsen, K.L., Doyle, J.S., Tavernini, M.M., Jewell, L.D., Rennie, R.P. and Fedorak, R.N. 2000. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology. 118: 1094-1105.
58. Mantzaris, G.J., Archavlis, E., Christoforidis, P., Kourtessas, D., Amberiadis, P., Florakis, N., Petraki, K., Spiliadi, C. and Triantafyllou, G. 1997. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am. J. Gastroenterol. 92: 454-456.
59. Mantzaris, G.J., Hatzis, A., Kontogiannis, P. and Triadaphyllou, G. 1994. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am. J. Gastroenterol. 89: 43-46.
60. Mantzaris, G.J., Petraki, K., Archavlis, E., Amberiadis, P., Kourtessas, D., Christidou, A. and Triantafyllou, G. 2001. A prospective randomised controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand. J. Gastroenterol. 36: 971-974.
61. Mao, Y., Nobaek, S., Kasravi, B., Adawi, D., Stenram, U., Molin, G., and Jeppsson, B. 1996. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 111: 334-344.
62. Marcus, R. and Watt, J. 1969. Seaweeds and ulcerative colitis in laboratory animals. Lancet. 2: 489-490.
63. Matsuda, H., Fujiyama, Y., Andoh, A., Ushijima, T., Kajinami, T., and Bamba, T. 2000. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 15: 61-68.
64. Mayberry, J.F., Ballantyne, K.C., Hardcastle, J.D., Mangham, C. and Pye, G. 1989. Epidemiological study of asymptomatic inflammatory bowel disease: the identification of cases during a screening programme for colorectal cancer. Gut. 30: 481-483.
65. Metcalf, A.M., Phillips, S.F., Zinsmeister, A.R., MacCarty, R.L., Beart, R.W. and Wolff, B.G. 1987. Simplified assessment of segmental colonic transit. Gastroenterology. 92: 40-47.
66. Monteiro, E., Fossey, J., Shiner, M., Draser, B.S. and Allison, A.C. 1971. Antibacterial antibodies in rectal and colonic mucosa in ulcerative colitis. Lancet. 1: 249-251.
67. Montgomery, S.M., Morris, D.L., Thompson, N.P., Subhani, J., Pounder, R.E. and Wakefield, A.J. 1998. Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort. Br. Med. J. 316: 1058-1059.
68. Onderdonk, A., Hermos, J. and Bartlett, J. 1977. The role of the intestinal microflora in experimental colitis. Am. J. Clin. Nutr. 30: 1819.
69. Onderdonk, A., Hermos, J., Dzink, J. and Bartlett, J. 1978. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology. 74: 521.
70. Onderdonk, A.B., and Bartlett, M.D. 1979. Bacteriological studies of experimental ulcerative colitis. Am. J. Clin. Nutr. 32: 258-265.
71. Onderdonk, A.B. 1983. Role of the intestinal microflora in ulcerative colitis. In: Human Intestinal Microflora in Health and Disease. D.J. Hentges, ed. Academic Press, London. p. 481-493.
72. Pathmakanthan, S., Thornley, J.P., and Hawkey, C.J. 1999. Mucosally associated bacterial flora of the human colon: quantitative and species specific differences between normal and inflammed colonic biopsies. Microb. Ecol. Hlth. Dis. 11: 169-174.
73. Pitcher, M.C.L. 1996. Sulphate-reducing bacteria, sulphur metabolism and ulcerative colitis. MD Thesis, University of Cambridge.
74. Pitcher, M.C.L., Beatty, E.R., and Cummings, J.H. 2000. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut. 46: 64-72.
75. Pitcher, M.C.L., Beatty, E.R., Harris, R.M., Waring, R.H., and Cummings, J.H. 1998. Sulfur metabolism in ulcerative colitis. Investigation of detoxification enzymes in peripheral blood. Dig. Dis. Sci. 43: 2080-2085.
76. Poxton, I.R., Brown, R., Sawyerr, A., and Ferguson, A. 1997. Mucosa-associated bacterial flora of the human colon. J. Med. Microbiol. 46: 85-91.
77. 2 microglobulin transgenic rats. J. Clin. Invest. 98: 945-953.
78. Rath, H.C., Ikeda, J.S., Linde, H.J. et al. 1999. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology. 116: 310-319.
79. Rath, H.C., Schultz, M., Freitag, R., Dieleman, L.A., Li, F., Linde, H.-J., Schölmerich, J. and Sartor, R.B. 2001. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69: 227-2285.
80. Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M., and Axon, A.T.R. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 636-639.
81. Rizzello, F., Gionchetti, P., Venturi, A., Ferretti, M., Peruzzo, S., Raspanti, X., Picard, M., Canova, N., Palazzini, E and Campieri, M. 1998. Rifaximin systemic absorption in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 54: 91-93.
82. Rizzello, F., Gionchetti, P., Ferrieri, A., Venturi, A., Brignola, C., Peruzzo, S., Raule, E., Descombe, J.J., Picard, M. and Campieri, M. 1997. Rifaximin, a non-absorbable antibiotic in treatment of steroid-resistant ulcerative colitis: A double-blind placebo controlled trial. Gastroenterology. 112: A1072.
83. Rizzello, F., Gionchetti, P., Venturi, A., Ferretti, M., Peruzzo, S., Raspanti, X., Picard, M., Canova, N., Palazzini, E. and Campieri, M. 1998. Rifaximin systemic absorption in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 54: 91-93.
84. Roediger, W.E.W., Duncan, A., Kapaniris, O., and Millard, S. 1993. Sulphide impairment of substrate oxidation in rat colonocytes: A biochemical basis for ulcerative colitis? Clin. Sci. 85: 1-5.
85. Ruseler van Embden, J.G.H., Schouten, W.R. and van Lieshout, L.M.C. 1994. Pouchitis: result of microbial imbalance? Gut. 35: 658-664.
86. Saitoh, S., Noda, S., Aiba, Y., Takagi, A., Sakamoto, M., Benno, Y., and Koga, Y. 2002. Bacteroides ovatus as the predominant commensal intestinal microbe causing a systemic antibody response in inflammatory bowel disease. Clin. Diagnost. Lab. Immunol. 9: 54-59.
87. Sartor, R.B., Rath, H.C. and Sellon, H.K. 1996. Microbial factors in chronic intestinal inflammation. Curr. Opin. Gastroenterol. 12: 327-333.
88. Satsangi, J., Landers, C.J., Welsh, K.I., Koss, K., Targan, S.R., and Jewell, D.P. 1998. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm. Bowel Dis. 4: 18-26.
89. Schultsz, C., Moussa, M., van Ketel, Tytgat, G.N.J., and Dankert, J. 1997. Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls. J. Clin. Pathol. 50: 573-579.
90. Schultsz C., van den Berg, F., Ten Kate, F.W., Tytgat, G.N.J., and Dankert, J. 1999. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 117: 1089-1097.
91. Schultz, M., Veltkamp, C., and Dieleman, L.A., 2002. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm. Bowel Dis. 8: 71-80.
92. Sellon, R.K., Tonkonogy, S., Schultz, M., Dieleman, L.A., Grenther, W., Balish, E., Rennick, D.M. and Sartor, R.B. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66: 5224-5231.
93. Steffen, R. 2001. Rifaximin: A nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J. Travel Med. 8: S34-S39.
94. Truelove, S.C. and Jewell, D.P. 1974. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. i: 1067-1070.
95. Turunen, U.M., Färkkila, M.A., Hakala, K., Seppälä, K., Sivonen, A., Ögren, M., Vuoristo, M., Valtonen, V.V. and Miettinen, T.A. 1998. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 115: 1072-1078.
96. Turunen, U.M., Saarinen, M., Farkkila, M.A., Valtonen, V.V. and Granfors, K. 1999. Antibody responses to Escherichia coli, Proteus mirabilis and Klebsiella Pneumoniae in ulcerative colitis during ciprofloxacin treatment. Gastroenterology. 116: A834.
97. Tvede, M., Bondesen, S., Nielsen, O.H., and Rasmussen, S.N. 1983. Serum antibodies to Bacteroides species in chronic inflammatory bowel disease. Scand. J. Gastroenterol. 18: 783-789.
98. Van der Waaij, D., Cohen, B.J. and Anver, M.R. 1974. Mitigation of experimental inflammatory bowel disease in guinea pigs by selective elimination of the aerobic gram-negative intestinal microflora. Gastroenterololgy. 67:460-472.
99. Venturi, A., Gionchetti, P. Rizzello, F., Johansson, R., Zucconi, E., Brigidi, P., Matteuzzi, D., and Campieri, M. 1999. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13: 1103-1108.
100. Vermeire, S. and Rutgeerts, P. 2001. Is there a role for antibiotics in Crohn's disease? In: Challenges in Inflammatory Bowel Disease. D.P. Jewell, B.F. Warren, and N.J. Mortensen, ed. Blackwell Science, Oxford. p. 121-125.
101. Victor, R.J., Kirsner, J.B., and Palmer, W. 1950. Failure to induce ulcerative colitis experimentally with filtrates of feces and rectal mucosa. Gastroenterology. 14: 398.
102. Videla, S., Vilaseca, J., Guarner, F., Salas, A., Treserra, F., Crespo, E., Antolin, M. and Malagelada, J.-R. 1994. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut. 35: 1090-1097.
103. Walmsey, R.S., Anthony, A., Slim, R., et al. 1998. Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J. Clin. Pathol. 51: 657-661.
104. Watt, J. and Marcus, R. 1973. Experimental ulcerative disease of the colon in animals. Gut. 14: 506-510.
105. Zinkevich, V., and Beech, I.B. 2000. Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic gut mucosa. FEMS Microbiol. Ecol. 34: 147-155.